Drug Profile
Research programme: virus-like particles - Agilvax
Alternative Names: AX 03; AX 14; Breast cancer immunotherapy - Agilvax; Dengue vaccine - Agilvax; Human papilloma virus vaccine - Agilvax; Malaria vaccine - Agilvax; Non-Hodgkin's lymphoma immunotherapy - Agilvax; Ovarian cancer immunotherapy - Agilvax; Pan-Ebola vaccine - Agilvax; Pan-Filovirus vaccine - Agilvax; Respiratory syncytial virus vaccine - AgilvaxLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Agilvax
- Class Virus-like particle vaccines
- Mechanism of Action CD44 antigen modulators; Immunogenetic stimulants; Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Dengue; Ebola virus infections; Human papillomavirus infections; Malaria; Non-Hodgkin's lymphoma; Ovarian cancer; Respiratory syncytial virus infections; Viral haemorrhagic fevers
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 28 May 2021 No recent reports of development identified for research development in Ebola-virus-infections(Prevention) in USA (Parenteral)
- 28 May 2021 No recent reports of development identified for research development in Viral-haemorrhagic-fevers(Prevention) in USA (Parenteral)